Bloedbiomarkers voor de ziekte van Alzheimer: de klinische waarde op de geheugenpoli

Read full text Summarise with VIRAT
Authors: Marleen Kloppenburg-Lagendijk, Ymkje MA Huitema, Argonde C. van Harten, Liesbeth Hempenius, Nicolaas A. Verwey
Cited by: 0
References: 44

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND: The development of highly sensitive assays has enabled the detection of biomarkers of Alzheimer's disease in blood. In this literature review, we discuss their clinical applicability based on recent studies. METHODS: A systematic search was conducted across Embase, Pubmed, Web of Science, Cochrane Central, and Google Scholar for studies published since 2021, using the search terms 'Alzheimer's Disease', 'Blood Biomarkers' and 'Memory Clinic'. RESULTS: Based on the 11 included studies, pTau181, pTau217, NfL and GFAP appear to be clinically relevant (diagnostic value, AUC > 0.7) as blood biomarker. CONCLUSIONS: Multiple blood biomarkers appear to be clinically relevant for diagnostics in a memory clinic setting. However, this conclusion is based on just 11 studies, highlighting the need for further research in real-world populations within memory clinics.

Fields of Study & Subjects

Dementia and Cognitive Impairment Research Alzheimer's disease research and treatments Cerebrospinal fluid and hydrocephalus

Publication details

Journal / source
Tijdschrift voor Gerontologie en Geriatrie
Volume
57
Issue
1
Pages
18–18
Publication date
31 March 2026
Language
NL